Stephen Faraone
American psychologist
- 2 min read
- 3 chapters
Related on Lably
Through Physiology, Psychology and Teacher
Education and career
Faraone graduated in 1978 from the State University of New York at Stony Brook with a BA in Psychology. He then went to the University of Iowa where he obtained his Master of Arts and Doctor of Philosophy. Faraone completed a postdoctoral clinical psychology internship and a research fellowship at Brown University. His post-doctoral mentor was Ming T. Tsuang.
After completing his post-doctoral fellowship at Brown, Faraone came to the Harvard Department of Psychiatry, where he began a career in psychiatric genetics. He first served as an instructor in 1985, and as an assistant professor in 1989. He was promoted to associate professor in 1993 and Full Professor in 2002. In 2004, he moved to SUNY Upstate Medical University where he is now Distinguished Professor of Psychiatry and of Neuroscience and Physiology. He is also Senior Scientific Advisor to the Research Program Pediatric Psychopharmacology at the Massachusetts General Hospital and a lecturer at Harvard Medical School. Faraone has been principal investigator on several grants from the National Institutes of Health and the Patient-Centered Outcomes Research Institute studying the nature, causes and treatment of ADHD. He is one of the world's leading authorities on the genetics of psychiatric disorders and has also made substantial contributions to research in psychopharmacology and research methodology. He led the International Consensus Statement on ADHD, and heads The ADHD Evidence Project, which curates evidence-based information about ADHD.
Faraone is a member of the European ADHD Guidelines Group (EAGG) and has founded the ADHD Molecular Genetics Network and the American Professional Society of ADHD and Related Disorders.
Sign in to keep reading
2 more chapters are free with a Lably account.
Research Funding and Financial Disclosures
Faraone's research has been funded by the U.S. National Institutes of Health, the Patient-Centered Outcomes Research Institute, the European Union and the following companies:
- Otsuka
- Shire/Takeda
- Ironshore
- McNeil
- Janssen
- Tris
- Supernus
He has received income or potential income from:
- Aardvark
- Aardwolf
- Otsuka
- Collegium
- Corium
- Supernus
- Mentavi
- AIMH
- Akili
- Alcobra
- Atentiv
- Aytu
- Axsome
- CogCubed
- Corium
- Eli Lilly
- Enzymotec
- Genomind
- Ironshore
- Janssen
- McNeil
- Neurolifesciences
- Neurovance
- Novartis
- Noven
- OnDosis
- Otsuka
- Pfizer
- Rhodes
- Shire
- Sunovion
- Takeda
- Sky Therapeutics
- Psyon
- Johnson & Johnson/Kenvue
- Vallon
With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. These disclosures are routinely reported in relevant publications.
Books published
- Tsuang MT, Faraone SV. The Genetics of Mood Disorders, Baltimore, MD: Johns Hopkins; 1990
- Faraone SV, Tsuang, D, Tsuang MT. Genetics of Mental Disorders: A Guide for Students, Clinicians, and Researchers, New York, NY: Guilford;1999.
- Faraone, S.V. Straight Talk About Your Child's Mental Health: What To Do When Something Seems Wrong, New York, NY: Guilford, 2003.
- Tsuang MT, Faraone SV & Glatt SG Schizophrenia: The Facts, Oxford University Press; 2011.
- Faraone, S.V. & Antshel, K. ADHD: Non-Pharmacologic Interventions Elsevier, 2014

